Triumvira Immunologics

Executive Summary

Triumvira Immunologics is a clinical-stage immuno-oncology company pioneering T cell therapies using its proprietary T cell Antigen Coupler (TAC) platform. Unlike traditional CAR-T or TCR therapies, TAC engages the natural T cell receptor signaling pathway, enabling targeted tumor destruction with potentially reduced toxicity. The company is advancing both autologous and allogeneic TAC-T cell programs, primarily focusing on solid tumors. As a private entity headquartered in Austin, Texas, Triumvira has not disclosed its total funding or valuation. The company's lead candidates are in Phase 1/2 trials, and near-term value hinges on clinical data demonstrating safety and efficacy. Given the early stage and lack of public market comparables, Triumvira represents a high-risk, high-reward opportunity in the competitive cell therapy space.

Upcoming Catalysts (preview)

• Q3 2026Initial Phase 1/2 data for TAC01-HER2 in HER2+ solid tumors60% success
• Q1 2027Phase 1/2 interim results for TAC01-CD19 in B-cell malignancies55% success
• Q4 2026Preclinical data updates for allogeneic TAC platform70% success